54 reports of this reaction
1.6% of all TIOCONAZOLE reports
#10 most reported adverse reaction
VAGINAL HAEMORRHAGE is the #10 most commonly reported adverse reaction for TIOCONAZOLE, manufactured by Insight Pharmaceuticals LLC. There are 54 FDA adverse event reports linking TIOCONAZOLE to VAGINAL HAEMORRHAGE. This represents approximately 1.6% of all 3,387 adverse event reports for this drug.
Patients taking TIOCONAZOLE who experience vaginal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VAGINAL HAEMORRHAGE is a less commonly reported adverse event for TIOCONAZOLE, but still significant enough to appear in the safety profile.
In addition to vaginal haemorrhage, the following adverse reactions have been reported for TIOCONAZOLE:
The following drugs have also been linked to vaginal haemorrhage in FDA adverse event reports:
VAGINAL HAEMORRHAGE has been reported as an adverse event in 54 FDA reports for TIOCONAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VAGINAL HAEMORRHAGE accounts for approximately 1.6% of all adverse event reports for TIOCONAZOLE, making it a notable side effect.
If you experience vaginal haemorrhage while taking TIOCONAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.